1. First of all, he has been engaged in gastrointestinal tumor surgery for more than 20 years and has always paid attention to the standardized, minimally invasive and individualized treatment of gastrointestinal tumors.
2. Secondly, the neoadjuvant chemotherapy for gastric cancer was systematically studied, and important progress was made.
3. Finally, we took the lead in combining perioperative comprehensive treatment mode with minimally invasive surgery technology, and completed the first clinical RCT study of laparoscopic surgery for gastric cancer after neoadjuvant chemotherapy in the world. We carried out and reported a series of studies on laparoscopic total gastrectomy and total laparoscopic surgery after neoadjuvant chemotherapy, published more than 50 academic papers, and the cumulative impact factor was > 360. Obtained 5 invention patents.